Stevens-Johnson syndrome after treatment with bendamustine

Leukemia Research

Volumn 36, Issue 7, 2012, Pages

  Lambertini, Matteo ^a   Del Mastro, Lucia ^a   Gardin, Giovanni ^a   Levaggi, Alessia ^a   Bighin, Claudia ^a   Giraudi, Sara ^a   Pronzato, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BENDAMUSTINE; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST TUMOR; CASE REPORT; CHOLESTATIC HEPATITIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LETTER; LUNG INFECTION; LYMPH NODE METASTASIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TUMOR BIOPSY;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HEPATITIS C; HUMANS; LYMPHOMA, NON-HODGKIN; NITROGEN MUSTARD COMPOUNDS; STEVENS-JOHNSON SYNDROME;

EID: 84862331816     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.006     Document Type: Letter

References (7)

1. Rummel M.J., Niederle L., Maschmeyer G., et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2009, 114. Abstract 405.
2. Hellerstedt B., Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003, 14:1792.
3. Dereure O., Navarro R., Rossi J.F., et al. Rituximab-induced vasculitis. Dermatology 2001, 203:83-84.
4. Lowndes S., Darby A., Mead G., et al. Steven's-Johnson Syndrome after treatment with rituximab. Ann Oncol 2002, 13:1948-1950.
5. Alamdari H.S., Pinter-Brown L., Cassarino D.S., et al. Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 2010, 16:1.
6. Henning J.S., Firoz B.F. Rituxan is not associated with Stevens Johnson Syndrome. Ann Oncol 2011, 22:1463-1464.
7. Parise L., Kahle J., Schlaak M., et al. Reply to Rituxan is not associated with Stevens-Johnson syndrome. Ann Oncol 2012, 23:807.